COVID-19 infection is associated with a roughly 50 percent increased risk of developing a new autoimmune disease, according to a 2025 meta-analysis covering 97 million individuals. The connection is not speculative: researchers have identified plausible biological mechanisms, documented waves of autoantibodies in hospitalized patients, and tracked new diagnoses of conditions ranging from inflammatory arthritis to thyroid disease in people who had no autoimmune history before catching SARS-CoV-2. The picture is more complicated than “virus causes autoimmunity,” though, and understanding where the evidence is strong, where it is still thin, and what it means for you personally requires looking at several layers of research.
The Population-Level Evidence
The most comprehensive look at this question comes from a systematic review and meta-analysis published in 2025 that pooled data from studies covering 97 million people. COVID-19 infection was linked to a 49 percent higher risk of new autoimmune-related diseases compared to uninfected controls.1PubMed. Association between COVID-19 and New-Onset Autoimmune Diseases: Updated Systematic Review and Meta-Analysis of 97 Million Individuals The conditions most strongly linked were those affecting blood vessels and connective tissue.
A separate large cohort study drilled into which specific autoimmune diseases carried the highest risk after infection. Of 24 autoimmune conditions examined, eight showed elevated risk in people who had been infected. Cutaneous vasculitis topped the list with an adjusted hazard ratio of about 1.8, meaning people who had COVID were roughly 80 percent more likely to develop the condition than those who hadn’t. Polyarteritis nodosa and hypersensitivity angiitis showed similar increases.2PubMed Central. New-onset autoimmune disease after COVID-19 These are not subtle differences. An 80 percent increase in risk sounds alarming, but it is worth keeping in mind that many of these conditions are rare to begin with, so the absolute number of additional cases remains relatively small even with a large relative jump.
How the Virus Turns the Immune System on Itself
Viruses have triggered autoimmune disease long before COVID came along. What makes SARS-CoV-2 particularly concerning is the range of mechanisms it seems to activate simultaneously.
The most discussed is molecular mimicry. Parts of the virus’s surface proteins look structurally similar to normal human proteins, and when the immune system mounts a defense against the virus, it can accidentally start attacking self-tissue that resembles the viral target. Researchers have used computational analysis to identify over 860 pairs of viral and human immune-system targets that share enough similarity to potentially trigger this kind of cross-reaction. The human proteins implicated include those associated with type 1 diabetes, autoimmune eye inflammation, and ankylosing spondylitis, among others.3ImmunoInformatics. Molecular mimicry impact of the COVID-19 pandemic: Sequence homology between SARS-CoV-2 and autoimmune diseases epitopes Both computer modeling and experimental lab work support this mechanism as plausible rather than just theoretical.4PubMed Central. Molecular mimicry and autoimmunity in the time of COVID-19
Molecular mimicry is not the only pathway. Bystander activation is another: the intense inflammatory response to SARS-CoV-2 damages healthy tissue, releasing self-proteins that the immune system had never been exposed to before. Once those proteins enter the bloodstream, immune cells can react to them as though they are foreign. There is also epitope spreading, where an immune response that started against one specific part of the virus gradually broadens to target additional proteins, including the body’s own. Researchers studying the brain have proposed that all of these pathways may work together to trigger neurological autoimmune conditions after COVID.5PubMed Central. COVID-19 as a Trigger of Brain Autoimmunity
A more recently studied pathway involves neutrophil extracellular traps, or NETs. During severe COVID, neutrophils (a type of white blood cell) release webs of DNA and proteins to trap the virus. Normally these traps get cleared away, but researchers found that hospitalized COVID patients had high levels of antibodies directed against the traps themselves. Those anti-NET antibodies interfered with the body’s ability to clean up the traps and were associated with worse respiratory outcomes and greater disease severity. The worry is that this cycle of NET formation, impaired clearance, and anti-NET antibody production mirrors what happens in established autoimmune diseases like lupus and certain forms of vasculitis.6PubMed Central. Autoantibodies stabilize neutrophil extracellular traps in COVID-19
Autoantibodies in People Who Never Had Autoimmune Disease
One of the more striking findings from the pandemic is how common autoantibodies are in COVID patients who had no autoimmune history. In one study, about half of hospitalized COVID patients had antibodies that recognized at least one protein typically targeted in connective-tissue diseases. Using a broader panel of targets, 80 percent of hospitalized patients showed antibodies against at least one self-protein found on cell surfaces or secreted in the body, compared to just 6 percent of healthy controls. Interferons, particularly type I interferon-alpha, were among the most frequently targeted.7Nature Communications. New-onset IgG autoantibodies in hospitalized patients with COVID-19
That interferon finding has practical significance. Type I interferons are a front-line antiviral defense. A separate multicenter study found that about 10 percent of critically ill COVID patients had antibodies that neutralized type I interferons, potentially weakening their ability to fight the virus and worsening disease severity.8PubMed Central. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study This creates a cruel feedback loop: the virus triggers autoantibodies that disable the immune molecules needed to control the virus, allowing worse infection, more tissue damage, and more opportunity for further autoimmune activation.
The presence of autoantibodies does not guarantee someone will develop a full-blown autoimmune disease. Many of these antibodies may be transient. But their sheer prevalence in hospitalized COVID patients, and the breadth of self-targets they recognize, is unusual for any single viral infection.
Which Conditions Have Been Linked to COVID?
The list of autoimmune conditions reported after COVID infection is long and spans nearly every organ system. Some connections rest on stronger evidence than others.
Joint Disease
Reactive arthritis, which typically follows infections of the gut or urinary tract, has been documented after COVID with joint symptoms appearing anywhere from about a week to nearly two months after the initial infection. The knee is the most commonly affected joint, and some patients also develop inflammatory low back pain or inflammation where tendons attach to bone.9Reumatología Clínica. Does post-COVID reactive arthritis exist? Experience of a tertiary care centre with a review of the literature Post-COVID clinics have also identified patients developing rheumatoid arthritis for the first time, suggesting the virus can precipitate chronic autoimmune joint disease in addition to the more self-limiting reactive form.10PubMed Central. Inflammatory Arthritis After COVID-19: A Case Series
Lupus
For people who already have systemic lupus erythematosus, COVID infection is a clear flare trigger. In one matched cohort study, about 18 percent of lupus patients who were hospitalized with COVID experienced a flare within six months, compared to 6 percent of unexposed controls. After adjusting for medications and disease history, the risk was nearly four times higher in the COVID group. Flares included kidney inflammation, severe blood cell destruction, and chest inflammation, and all required treatment escalation.11PLOS ONE. Risk of systemic lupus erythematosus flare after COVID-19 hospitalization: A matched cohort study New-onset lupus kidney disease in people with no prior lupus diagnosis has also been reported after COVID, though this evidence comes from case reports rather than large studies.12PubMed Central. New-onset lupus nephritis associated with COVID-19 infection
Thyroid Disease
COVID appears capable of destabilizing thyroid autoimmunity. Case reports describe patients with long-stable Hashimoto’s thyroiditis who developed Graves’ disease within a month of infection, and patients with previously controlled Graves’ disease who experienced worsening. In each case, thyroid-stimulating antibody levels increased after the infection. Even patients with no prior thyroid disease have developed thyroid inflammation after COVID.13PubMed Central. Development of autoimmune thyroid disease after COVID-19 infection: case report
Neurological Autoimmunity
Guillain-Barré syndrome, a condition where the immune system attacks peripheral nerves causing muscle weakness, has been reported after both COVID infection and COVID vaccination. Some countries observed increased Guillain-Barré cases during the pandemic, consistent with SARS-CoV-2 serving as a trigger.14PubMed Central. The Impact of COVID-19 on the Guillain-Barré Syndrome Incidence The occurrence of the condition after both infection and vaccination points to shared pathways of immune activation rather than something unique to the virus’s direct effects.15PubMed Central. Guillain-Barré syndrome (GBS) after severe/critical COVID-19 or COVID-19 vaccination
Blood Disorders
Immune thrombocytopenic purpura, a condition where the immune system destroys the body’s own platelets and causes bleeding or bruising, has emerged as a recognized complication of COVID. The proposed mechanisms involve disrupted immune-cell development, overactive inflammatory pathways, and a form of cell death called pyroptosis that spills cellular contents into the bloodstream, further stoking the autoimmune response.16PubMed Central. COVID-19-induced immune thrombocytopenic purpura; Immunopathogenesis and clinical implications
Type 1 Diabetes
This one deserves a nuance flag. A systematic review of case reports found 37 people who developed new type 1 diabetes during or shortly after COVID infection, most of them children with a median age of about 12.17PubMed Central. COVID-19 induced type 1 diabetes: A systematic review of case reports and series Those case reports are concerning, but a large Danish registry study found no statistically significant association between SARS-CoV-2 infection and new type 1 diabetes diagnoses at the population level.18Diabetes Care. Association of COVID-19 and Development of Type 1 Diabetes: A Danish Nationwide Register Study The discrepancy likely reflects the difference between individual cases, where the virus was a plausible trigger for someone already genetically predisposed, and the broader population, where the overall risk increase may be too small to detect. This is a good reminder that case reports can signal real phenomena while population-level data put those phenomena in proportion.
Children and MIS-C
The pediatric angle to COVID-triggered autoimmunity came into sharp focus early in the pandemic with multisystem inflammatory syndrome in children, known as MIS-C. This condition, which typically appears weeks after a SARS-CoV-2 infection, involves severe inflammation affecting multiple organs. Researchers analyzing the immune profile of MIS-C patients found a strong autoimmune signature: the children had autoantibodies targeting both widely expressed and tissue-specific proteins throughout the body. The more severe the case, the more intense the autoimmune and inflammatory markers. The pattern suggests that widespread tissue damage during the initial infection releases self-proteins that then become new targets for the immune system.19Journal of Clinical Investigation. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children MIS-C cases have dropped dramatically since widespread vaccination and natural immunity took hold, but the condition illustrated how powerfully SARS-CoV-2 could redirect a young immune system against the body’s own tissues.
Does Vaccination Carry the Same Risk as Infection?
This is one of the most important practical questions, and the evidence is reassuring. A large population-based cohort study from Hong Kong found that COVID-vaccinated patients who later got infected had a meaningfully lower risk of developing several autoimmune conditions compared to unvaccinated patients who got infected. The reductions were substantial: vaccinated patients had roughly 40 to 70 percent lower risk for conditions including autoimmune arthritis, immune-mediated platelet destruction, Graves’ disease, antiphospholipid syndrome, and lupus.20eClinicalMedicine. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study
A study of 112 million people specifically looked at autoimmune blistering diseases, a category of skin conditions driven by autoantibodies. People who had COVID infection faced more than three times the risk compared to those who were vaccinated, and for one specific subtype, pemphigus, the risk was more than five times higher in the infected group.21PubMed. COVID-19 infection is associated with an elevated risk for autoimmune blistering diseases while COVID-19 vaccination decreases the risk: A large-scale population-based cohort study of 112 million individuals The vaccine introduces a controlled exposure to a single viral protein (the spike protein), which generates immune memory without the massive tissue damage, intense inflammation, and broad antigen release of an actual infection. That distinction seems to be what keeps the autoimmune risk lower.
Vaccination is not completely risk-free when it comes to autoimmunity. Certain rare autoimmune events, including Guillain-Barré syndrome and vaccine-induced immune thrombocytopenia, have been documented after COVID vaccination, particularly with certain vaccine types. But the scale of these events is orders of magnitude smaller than the autoimmune toll from infection itself.
The Long COVID Connection
Autoimmunity has become one of the leading hypotheses for why some people develop long-lasting symptoms after COVID. Several research groups have found autoantibodies in long COVID patients, both antibodies that were present before the infection and new ones that appeared afterward. Whether these antibodies are actually causing the chronic fatigue, brain fog, and exercise intolerance that define long COVID, or whether they are bystanders of ongoing immune dysfunction, is a question that researchers are actively debating.22PubMed. Autoimmunity in long COVID
A recent study using tissue-specific autoantibody profiling found that 83 percent of long COVID patients had detectable autoantibodies compared to 53 percent of recovered controls. The long COVID group showed a particularly striking pattern of antibodies targeting blood vessels, with vascular autoreactivity seen in about a third of patients compared to 8 percent of controls. Most of these antibodies were of the IgM type, which typically represents an early or ongoing immune response rather than a mature, long-established one. Over time, some patients developed additional antibody types, suggesting the autoimmune process was evolving rather than resolving.23SpringerLink / Geroscience. Tissue-specific autoantibody signatures reveal immune alterations undetected by routine serology in long COVID
Who Is Most Susceptible?
Not everyone who gets COVID will develop autoimmune problems, and the question of who is most vulnerable does not have a clean answer yet. Genetic factors almost certainly play a role. Specific variants in human leukocyte antigen (HLA) genes, which help the immune system distinguish self from non-self, have been linked to autoimmune reactions following COVID. Certain HLA types have been associated with vaccine-triggered thyroid inflammation and immune thrombocytopenia, suggesting that genetic makeup helps determine whether a given immune exposure tips into autoimmunity.24PubMed Central. An overview of HLA variants in COVID-19 vaccine-induced autoimmunity.
Sex is another factor. Autoimmune diseases in general are far more common in women, and conditions that develop after infections follow the same pattern. Research on post-acute infection syndromes, including long COVID, shows that females are disproportionately affected in both prevalence and symptom profile. The reasons likely involve hormonal influences on immune regulation and sex-based differences in how vigorously the immune system responds to infection. This area is still poorly understood, and researchers have flagged it as needing dedicated sex-based studies rather than the pooled analyses that dominate the field so far.
Severity of the initial infection also seems to matter. The autoantibody studies cited above primarily found elevated levels in hospitalized patients. Whether milder or asymptomatic infections carry the same autoimmune risk at a lower level, or whether a threshold of tissue damage is necessary to initiate the process, remains an open question.
Treatment When COVID Triggers Autoimmunity
When an autoimmune condition develops after COVID, treatment generally follows the same playbook as it would for the non-COVID-triggered version of that disease. Corticosteroids are typically first-line for acute flares. Beyond that, intravenous immunoglobulin (IVIG) therapy has drawn attention for its ability to both calm excessive inflammation and modulate autoimmune responses through multiple mechanisms, making it a useful option when the immune system is overactive on several fronts at once.25PubMed. COVID-19-associated Autoimmune and Inflammatory Diseases: Molecular Mechanisms and the Role of IVIG Therapy
For cases that do not respond to standard therapies, more aggressive approaches may work. One documented case involved a patient with post-COVID autoimmune encephalitis, a brain inflammation causing near-complete loss of speech, who failed to improve on intravenous steroids. Plasmapheresis, a procedure that filters antibodies out of the blood, produced dramatic improvement within a day, with the patient progressing from single-word utterances to near-complete sentences.26PubMed Central. Successful Treatment of Post-coronavirus Disease 2019 (COVID-19) Autoimmune Encephalitis With Plasmapheresis After a Failed Trial of Steroids That is a single case, but it illustrates a principle: if autoantibodies are driving the problem, physically removing them from circulation can sometimes produce results where suppressing the immune system more broadly does not.
The broader clinical challenge is timing. Autoimmune diseases are easier to manage when caught early. If you develop new joint pain, unusual fatigue, skin changes, numbness or weakness in the limbs, or unexplained thyroid symptoms in the weeks to months after a COVID infection, flagging the COVID history to your doctor may prompt earlier testing for autoimmune markers than would otherwise happen. That context can make the difference between a quick diagnosis and months of diagnostic uncertainty.
Why Standard Blood Tests Can Miss Post-COVID Autoimmunity
One underappreciated problem is that routine autoimmune blood panels may not catch what is happening after COVID. Standard tests look for well-established autoantibody markers associated with classical autoimmune diseases. But the autoantibodies produced after SARS-CoV-2 infection can target unconventional proteins, including cell-surface and secreted proteins that are not part of standard screening panels. The tissue-specific autoantibody profiling study mentioned earlier found vascular autoreactivity in long COVID patients that routine serology completely missed.23SpringerLink / Geroscience. Tissue-specific autoantibody signatures reveal immune alterations undetected by routine serology in long COVID This means a patient can have clinically meaningful autoimmune activity and still get “normal” results on a standard panel, which can be frustrating and lead both patients and clinicians to dismiss the autoimmune hypothesis prematurely. Expanded autoantibody testing is not yet widely available outside research settings, but awareness that negative routine tests do not rule out post-COVID autoimmunity is itself a useful piece of information for anyone navigating this situation.